Nichi-Iko Pharmaceutical will transfer its authorized generic (AG) versions of three brands to a Meiji Group company, including one for Allegra (fexofenadine) — Japan’s first AG, approved in 2012 and launched the following year. Nichi-Iko, Sanofi, and Meiji Seika Pharma…
To read the full story
Related Article
- Sanofi, Nichi-Iko to Dissolve Joint Venture at Year-End
October 26, 2021
BUSINESS
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





